SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21: 92-98.
  • 2
    Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced larynx cancer. N Engl J Med. 2003; 349: 2091-2098.
  • 3
    Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Cancer. 1990; 66: 1861-1868.
  • 4
    Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck. 2001; 23: 579-589.
  • 5
    Forastiere AA, Ang K, Brizel D, et al. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2.2008. Fort Washington, PA: NCCN; 2008.
  • 6
    Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25: 581-611.
  • 7
    Kyzas PA, Cunha IW, Ionnidis JPA. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005; 11: 1434-1440.
  • 8
    Teicher BA, Holden SA, Gulshan A, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer. 1995; 61: 732-737.
  • 9
    Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of action. Clin Cancer Res. 2003; 9: 1957-1971.
  • 10
    Lee C-G, Heijn M, Di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000; 60: 5565-5570.
  • 11
    Seiwert TY, Haraf DJ, Cohen EW, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008; 26: 1732-1741.
  • 12
    Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22: 2184-2191.
  • 13
    Fury MG, Zahalsky AJ, Wong RJ, et al. A phase II trial of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs. 2007; 25: 165-172.
  • 14
    Guo M, Gong Y, Deavers M, et al. Evaluation of commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol. 2008; 46: 274-280.
  • 15
    Denis F, Garaud P, Bardet E, et al. Final results of the 94–01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol. 2004; 22: 69-76.
  • 16
    Soo K-C, Tan E-H, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005; 93: 279-286.
  • 17
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578.
  • 18
    List MA, Ritter-Sterr C, Lansky SB. A performance status scale for head and neck cancer patients. Cancer. 1990; 66: 564-569.
  • 19
    Garden AS, Harris J, Vokes EE, et al. Preliminary results of radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2004; 22: 2856-2864.
  • 20
    Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal cancer (RTOG 0615): a phase II multi-institutional trial. Lancet Oncol. 2011; 13: 172-180.
  • 21
    Fury MG, Sherman E, Ho A, Lee NY, Pfister DG. Bevacizumab, cetuximab, and cisplatin with IMRT (Intensity-Modulated Radiation Therapy) for patients with stage III/IV head and neck squamous cell carcinoma. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00968435?term=Furyplusbevacizumab&rank=1. [Accessed February 10, 2012.]
  • 22
    Vidal L, Gillison ML. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am. 2008; 22: 1125-1142.
  • 23
    Gillison ML, Zhang Q, Ang K, et al. Analysis of the effect of p16 and tobacco pack-years on overall and progression-free survival for patients with oropharynx cancer in Radiation Therapy Oncology Group protocol 9003 [abstract]. J Clin Oncol. 2010; 28: 18s. Abstract 5510.
  • 24
    Hammarstedt L, Dahlstrand H, Lindquist D, et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol. 2007; 127: 988-992.
  • 25
    Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
  • 26
    Salama JK, Haraf DJ, Stenson KM, et al. A randomized phase II study of 5-fluoruracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0–1 head and neck cancers. Ann Oncol. 2011; 22: 2304-2309.